GLP-1R agonist therapy for diabetes: benefits and potential risks
The DOI matches its Crossref record; 41 of the 42 references it cites were found in a registry or an index.
Abstract
PURPOSE OF REVIEW: Glucagon-like peptide 1 receptor (GLP-1R) agonists provide good glycemic control combined with low hypoglycemia risk and weight loss. Here, we summarize the recently published data for this therapy class, focusing on sustainability of action, use in combination with basal insulin, and the efficacy of longer acting agents currently in development. The safety profile of GLP-1R agonists is also examined. RECENT FINDINGS: GLP-1R agonists provide sustained efficacy and their combination with basal insulin is well tolerated, providing additional glycemic control and weight benefits compared with basal insulin alone. Data suggest that the convenience of longer acting agents may be at the expense of efficacy. Despite the initial concerns, most evidence indicates that GLP-1R agonists do not increase the risk of pancreatitis or thyroid cancer. However, the extremely low incidence of these events means further investigations are required before a causal link can be eliminated. Large-scale clinical trials investigating the long-term cardiovascular safety of this therapy class are ongoing and may also provide important insights into pancreatic and thyroid safety. SUMMARY: GLP-1R agonists offer sustained glycemic efficacy, weight loss benefits, and a low risk of hypoglycemia. The results of ongoing trials should help to clarify the safety of this therapy class.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Like any medication, GLP-1RAs may have side effects, including nausea, vomiting, diarrhea, and injection site reactions. These side effects are often mild and tend to improve over time.72–74”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [73]
Citations
Cites
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896 · cited 2×
“GLP-1R agonists carry a low risk of hypoglycemia because of the glucose-dependent nature of their activity, although this risk is increased in patients receiving concomitant sulfonylurea or insulin [4].”
BackgroundGlucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928
Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503 · cited 5×
“A1C data from clinical trials of GLP-1R agonists approved for use in patients with type 2 diabetes Study ID, name and reference Investigational product (background therapy in all arms) Trial duration (weeks) Change in A1C from baseline Comparator Change in A1C from baseline P value for difference Clinical trials of ap…”
BackgroundInfluentialPancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies
Elashoff, M., Matveyenko, A. V., Gier, B., Elashoff, R., & Butler, P. C. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.02.018 · Cited by 944 · cited 1×
“demonstrated an increased risk of pancreatitis with exenatide and the DPP-4 inhibitor sitagliptin [48]; however, it has been criticized for weaknesses in the methodology, including the inherent reporting bias in the source data, problems associated with diagnostic definitions and lack of analysis of confounding factor…”
BackgroundNikolaidis, L. A., Mankad, S., Sokos, G. G., Miske, G., Shah, A., Elahi, D., & Shannon, R. P. (2004) · Circulation · doi:10.1161/01.cir.0000120505.91348.58 · Cited by 901 · cited 1×
“Published data also suggests that GLP-1 potentially could provide cardioprotective benefits and enhance cardiovascular function, encouraging further scientific and clinical exploration [6,7].”
BackgroundPlasma Insulin Response to Oral and Intravenous Glucose Administration1
ELRICK, H., STIMMLER, L., HLAD, C. J., & ARAI, Y. (1964) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-24-10-1076 · Cited by 857 · cited 1×
“0b013e32835edb32 INTRODUCTION In healthy individuals, oral ingestion of nutrients promotes a greater insulin response than parenteral infusion of an equivalent glucose load [1].”
BackgroundGöke, R., Fehmann, H. C., Linn, T., Schmidt, H., Krause, M., Eng, J., & Göke, B. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)36565-2 · Cited by 837
Nyström, T., Gutniak, M. K., Zhang, Q., Zhang, F., Holst, J. J., Ahrén, B., & Sjöholm, Å. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00237.2004 · Cited by 680
Bjerre Knudsen, L., Madsen, L. W., Andersen, S., Almholt, K., de Boer, A. S., Drucker, D. J., Gotfredsen, C., Egerod, F. L., Hegelund, A. C., Jacobsen, H., et al. (2010) · Endocrinology · doi:10.1210/en.2009-1272 · Cited by 672 · cited 2×
“However, these observations have not been replicated in primates or humans and are thought to be a rodent phenomenon because of the higher density of GLP-1Rs on rodent C-cells [50,51].”
BackgroundFarilla, L., Bulotta, A., Hirshberg, B., Li Calzi, S., Khoury, N., Noushmehr, H., Bertolotto, C., Di Mario, U., Harlan, D. M., & Perfetti, R. (2003) · Endocrinology · doi:10.1210/en.2003-0323 · Cited by 664 · cited 1×
“In preclinical studies, GLP-1 has been shown to protect b-cells [5].”
Background
Cited by
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects
Zhao, X., Wang, M., Wen, Z., Lu, Z., Cui, L., Fu, C., Xue, H., Liu, Y., & Zhang, Y. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.721135 · Cited by 463
Oxidative and endoplasmic reticulum stress in β-cell dysfunction in diabetes
Hasnain, S. Z., Prins, J. B., & McGuckin, M. A. (2016) · Journal of Molecular Endocrinology · doi:10.1530/jme-15-0232 · Cited by 253
Weight Management in Type 2 Diabetes: Current and Emerging Approaches to Treatment
Van Gaal, L., & Scheen, A. (2015) · Diabetes Care · doi:10.2337/dc14-1630 · Cited by 221
Zhang, Y., Parajuli, K. R., Fava, G. E., Gupta, R., Xu, W., Nguyen, L. U., Zakaria, A. F., Fonseca, V. A., Wang, H., Mauvais-Jarvis, F., et al. (2019) · Diabetes · doi:10.2337/db18-0317 · Cited by 104
Effects of glucagon-like peptide-1 receptor agonists on renal function
Filippatos, T. D., & Elisaf, M. S. (2013) · World Journal of Diabetes · doi:10.4239/wjd.v4.i5.190 · Cited by 97
Exenatide exerts cognitive effects by modulating the BDNF-TrkB neurotrophic axis in adult mice
Bomba, M., Granzotto, A., Castelli, V., Massetti, N., Silvestri, E., Canzoniero, L. M. T., Cimini, A., & Sensi, S. L. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.12.009 · Cited by 69
Bomba, M., Granzotto, A., Castelli, V., ONOFRJ, M. C., Lattanzio, R., Cimini, A., & Sensi, S. L. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-190237 · Cited by 69
Optimal therapy of type 2 diabetes: a controversial challenge
Dardano, A., Penno, G., Prato, S. D., & Miccoli, R. (2014) · Aging · doi:10.18632/aging.100646 · Cited by 68
Past, present and future of latent autoimmune diabetes in adults
Liu, B., Xiang, Y., Liu, Z., & Zhou, Z. (2020) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3205 · Cited by 50
An Updated Review on Cancer Risk Associated with Incretin Mimetics and Enhancers
Tseng, C.-H., Lee, K.-Y., & Tseng, F.-H. (2015) · Journal of Environmental Science and Health, Part C · doi:10.1080/10590501.2015.1003496 · Cited by 49
“There are several randomized controlled trials being conducted for evaluating the cardiovascular safety of either DPP-4 inhibitors or GLP-1R agonists [53, 178, 179].”
BackgroundStructural analysis of the dual agonism at GLP-1R and GCGR
Li, Y., Zhou, Q., Dai, A., Zhao, F., Chang, R., Ying, T., Wu, B., Yang, D., Wang, M., & Cong, Z. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2303696120 · Cited by 50
Cong, Z., Zhou, Q., Li, Y., Chen, L.-N., Zhang, Z.-C., Liang, A., Liu, Q., Wu, X., Dai, A., Xia, T., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2200155119 · Cited by 41
Prevention of type 2 Diabetes Mellitus: Potential of pharmacological agents
Samson, S. L., & Garber, A. J. (2016) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2016.06.005 · Cited by 37
Self-citationThe Effect of Exenatide on Thyroid-Stimulating Hormone and Thyroid Volume
Sencar, M. E., Sakız, D., Çalapkulu, M., Hepşen, S., Kızılgül, M., Ozturk, U. İ., Uçan, B., Bayram, M., Cagir, B. B., Akın, Ş., et al. (2019) · European Thyroid Journal · doi:10.1159/000501895 · Cited by 38
Srinivasan, D. K., Ojo, O. O., Abdel‐Wahab, Y. H. A., Flatt, P. R., Guilhaudis, L., & Conlon, J. M. (2014) · Peptides · doi:10.1016/j.peptides.2014.02.002 · Cited by 29
Wysham, C. H., Lin, J., & Kuritzky, L. (2017) · Postgraduate Medicine · doi:10.1080/00325481.2017.1297669 · Cited by 26
Cyclic alpha-conotoxin peptidomimetic chimeras as potent GLP-1R agonists
Swedberg, J. E., Schroeder, C. I., Mitchell, J. M., Durek, T., Fairlie, D. P., Edmonds, D. J., Griffith, D. A., Ruggeri, R. B., Derksen, D. R., Loria, P. M., et al. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.08.046 · Cited by 26
Flintoff, J. M., Kesby, J. P., Siskind, D. J., & Burne, T. H. J. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1951702 · Cited by 25
Tee, S. A., Tsatlidis, V., & Razvi, S. (2023) · Clinical Endocrinology · doi:10.1111/cen.14901 · Cited by 27
Allosteric Modalities for Membrane-Bound Receptors: Insights from Drug Hunting for Brain Diseases
Coughlin, Q., Hopper, A. T., Blanco, M.-J., Tirunagaru, V. G., Robichaud, A. J., & Doller, D. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01651 · Cited by 23
Incretins and microRNAs: Interactions and physiological relevance
Radbakhsh, S., Sathyapalan, T., Banach, M., & Sahebkar, A. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104662 · Cited by 21
Mezquita‐Raya, P., de Arellano, A. R., Kragh, N., Vega-Hernandez, G., Pöhlmann, J., Valentine, W. J., & Hunt, B. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0239-6 · Cited by 19
Zhang, P., Zhao, Z., Zhang, L., Wu, W., Xu, Y., Pan, D., Wang, F., & Yang, M. (2019) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2019.08.002 · Cited by 18
Artigas, C. F., Stokes, V. J., Tan, G. D., & Theodorakis, M. J. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1052740 · Cited by 16
Baik, S. H., & McDonald, C. J. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-000940 · Cited by 16
GLP-1 Receptor Agonists: Practical Considerations for Clinical Practice
Triplitt, C. L., & Solis‐Herrera, C. (2015) · The Science of Diabetes Self-Management and Care · doi:10.1177/0145721715607981 · Cited by 17
Girdhar, K., Thakur, S., Gaur, P., Choubey, A., Dogra, S., Dehury, B., Kumar, S., Biswas, B., Dwivedi, D. K., Ghosh, S., et al. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.101889 · Cited by 14
Exenatide Treatment Reduces Thyroid Gland Volume, but Has No Effect on the Size Of Thyroid Nodules
Köseoğlu, D., Başer, Ö. Ö., Berker, D. S., & Cekic, S. G. (2020) · Acta Endocrinologica (Bucharest) · doi:10.4183/aeb.2020.275 · Cited by 20
Şahin, S., & Dege, N. (2022) · TURKISH JOURNAL OF CHEMISTRY · doi:10.55730/1300-0527.3460 · Cited by 13
Drug repositioning in thyroid cancer treatment: the intriguing case of anti-diabetic drugs
Greco, A., Coperchini, F., Croce, L., Magri, F., Teliti, M., & Rotondi, M. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1303844 · Cited by 18
Differential effects of prandial and non-prandial GLP-1 receptor agonists in type 2 diabetes therapy
Davidson, J. A. (2015) · Postgraduate Medicine · doi:10.1080/00325481.2015.1096743 · Cited by 12
GLP-1R mediates idebenone-reduced blood glucose in mice
Zhao, X., Zeng, Q., Yu, S., Zhu, X., Hu, B., Deng, L., Zhang, Y., & Liu, Y. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117202 · Cited by 10
Advances in managing type 2 diabetes: challenging old paradigms and developing new ones
Sattar, N. A. (2014) · F1000Prime Reports · doi:10.12703/p6-42 · Cited by 13
Mi, B., Xu, Y., Pan, D., Wang, L., Yang, R., Yu, C., Wan, W., Wu, Y., & Yang, M. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.01.184 · Cited by 11
GLP-1(28-36)amide, the Glucagon-like peptide-1 metabolite: friend, foe, or pharmacological folly?
Whitehead, J. P., Taing, M., & Rose, F. J. (2014) · Drug Design Development and Therapy · doi:10.2147/dddt.s35723 · Cited by 11
Kannan, S., & Nasr, C. E. (2015) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.81a.13066 · Cited by 8
Management of Type 2 Diabetes Mellitus
Dungan, K. M. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-18907-1.00048-2 · Cited by 10
Protein Uncoupling as an Innovative Practice in Diabetes Mellitus Treatment: A Metabolic Disorder
Chaudhary, R., Gupta, S., & Chauhan, S. (2022) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530322666220902143401 · Cited by 7
Seguridad cardiovascular de los antidiabéticos no insulínicos. Posicionamiento científico SEMERGEN
Prieto-Díaz, M. Á., Samper, J. M. C., Cervantes, C. E., & Molinera, V. G. (2014) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2014.04.005 · Cited by 7
Asemi, Z., Salami, R., Salami, M., Mafi, A., Aarabi, M. H., & Vakili, O. (2022) · Current Molecular Pharmacology · doi:10.2174/1874467215666220829102020 · Cited by 7
Lopez-Saura, P., & Herrera-Martínez, B. A.-C. L. (2013) · Journal of Diabetes & Metabolism · doi:10.4172/2155-6156.1000285 · Cited by 9
Dulaglutide: a novel once-weekly glucagon-like peptide-1 receptor agonist
Naver, S. V., Jimenez‐Solem, E., Christensen, M., Andersen, J. T., & Knop, F. K. (2014) · Clinical Investigation · doi:10.4155/cli.14.65 · Cited by 6
Gliozzi, M., Coppoletta, A. R., Cardamone, A., Carresi, C., Mollace, R., Musolino, V., & Mollace, V. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107744 · Cited by 3
Cancer Incidence Among Users of Glucagon-Like Peptide-1 Receptor Agonists
Rashid, Z., Woldesenbet, S., Khalil, M., Altaf, A., Zindani, S., Mevawalla, A., Sarfraz, A., Mumtaz, K., & Pawlik, T. M. (2026) · Journal of General Internal Medicine · doi:10.1007/s11606-026-10300-1 · Cited by 1
Peripheral actions of GPCRs in energy homeostasis: view from the Chair
Bouvier, M. (2014) · International Journal of Obesity Supplements · doi:10.1038/ijosup.2014.2 · Cited by 1
Is Liraglutide Associated With Myocardial Protection in ST-Elevation Myocardial Infarction?
Flather, M. D. (2016) · Circulation Cardiovascular Imaging · doi:10.1161/circimaging.116.005684 · Cited by 1
Hart, N. J. (2013) · UA Campus Repository (The University of Arizona)
Krentz, A. J., Heinemann, L., & Hompesch, M. (2014) · Springer eBooks · doi:10.1007/978-1-4471-4920-0_2
Prieto-Díaz, M. Á., Escobar, C., & Molinera, V. G. (2014)
Krajewska, J., Krajewski, W. R., & Zatoński, T. (2019) · Springer eBooks · doi:10.1007/978-3-030-11815-0_59
A review of current knowledge: Role of diabetes, cancer and cytochrome P450
Samani, K., Sharma, U., Joshi, A. R., Surendra, V., & Pm, M. (2020) · IP Journal of diagnostic pathology and oncology/IP journal of diagnostic pathology and oncology/Journal of diagnostic pathology and oncology · doi:10.18231/j.jdpo.2020.048
Wojciechowska, J. K., Krajewski, W. R., Zatoński, T., & Rodríguez‐Saldaña, J. (2023) · Springer eBooks · doi:10.1007/978-3-031-25519-9_63
Contrôle de la masse des cellules bêta et de l'homéostasie du glucose par CaMK1 D
Mészáros, G. (2015) · theses.fr (ABES) · doi:10.70675/c3eeec37z9992z4127z8199z4bbcb58778c8
Liang, J., Bo, L., Miao, X., Guo, X., Xu, J., He, J., & Ye, X. (2026) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-026-01190-4
BindingDB Entry 50046770: Cyclic alpha-conotoxin peptidomimetic chimeras as potent GLP-1R agonists.
BindingDB (2016) · UC San Diego · doi:10.7270/q2jh3p05
Metadata
- Authors
- Samson, S. L., & Garber, A.
- Affiliations
- Baylor College of Medicine (US)
- Corresponding author
- Samson, Susan L.
- ORCID
- Samson, Susan L.
- Venue
- Current Opinion in Endocrinology, Diabetes & Obesity
- Published
- 2013-04
- Volume
- 20
- Issue
- 2
- Pages
- 87-97
- ISSN
- 1752-296X (ISSN-L)
- OpenAlex
- W2123127609
- Cited by
- 55
- References
- 42
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 2 · 2023: 4 · 2022: 5 · 2021: 2 · 2020: 4 · 2019: 5 · 2018: 2 · 2017: 3 · 2016: 4 · 2015: 9 · 2014: 9 · 2013: 3
- FWCI
- 1.27
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Opinion in Endocrinology Diabetes and Obesity (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Intarcia Therapeutics
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK079638)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- GLP-1 receptor agonists, type 2 diabetes, glycemic control, weight loss, hypoglycemia risk, pancreatitis risk, thyroid cancer risk, cardiovascular safety, drug safety
- MeSH terms
- Glucagon-Like Peptide-2 Receptor, Liraglutide, Exenatide, Blood Glucose, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Glucagon-Like Peptides, Female, Humans, Hypoglycemia, Hypoglycemic Agents, Immunoglobulin Fc Fragments, Insulin, Male, Pancreatitis, Peptides, Recombinant Fusion Proteins, Thyroid Neoplasms, Venoms, Randomized Controlled Trials as Topic, Treatment Outcome, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.